Pavel Mohr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7109694/publications.pdf Version: 2024-02-01



DAVEL MOHD

#	Article	IF	CITATIONS
1	Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia. CNS Drugs, 2006, 20, 389-409.	2.7	385
2	Increase in prevalence of current mental disorders in the context of COVID-19: analysis of repeated nationwide cross-sectional surveys. Epidemiology and Psychiatric Sciences, 2020, 29, e173.	1.8	143
3	Psychopathy and Violent Behavior Among Patients With Schizophrenia or Schizoaffective Disorder. Psychiatric Services, 1999, 50, 787-792.	1.1	127
4	Effect of Low-Frequency rTMS on Electromagnetic Tomography (LORETA) and Regional Brain Metabolism (PET) in Schizophrenia Patients with Auditory Hallucinations. Neuropsychobiology, 2007, 55, 132-142.	0.9	97
5	Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2012, 32, 46-55.	0.7	71
6	Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS). Journal of Psychiatric Practice, 2012, 18, 269-280.	0.3	66
7	White matter changes in first episode psychosis and their relation to the size of sample studied: A DTI study. Schizophrenia Research, 2015, 162, 22-28.	1.1	56
8	Prevalence of current mental disorders before and during the second wave of COVID-19 pandemic: An analysis of repeated nationwide cross-sectional surveys. Journal of Psychiatric Research, 2021, 139, 167-171.	1.5	49
9	Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. Journal of Steroid Biochemistry and Molecular Biology, 2013, 133, 77-83.	1.2	48
10	The double-blind sham-controlled study of high-frequency rTMS (20 Hz) for negative symptoms in schizophrenia: negative results. Neuroendocrinology Letters, 2006, 27, 209-13.	0.2	48
11	The Application of Vagus Nerve Stimulation and Deep Brain Stimulation in Depression. Neuropsychobiology, 2011, 64, 170-181.	0.9	44
12	Individualized rTMS neuronavigated according to regional brain metabolism (18FGD PET) has better treatment effects on auditory hallucinations than standard positioning of rTMS: a double-blind, sham-controlled study. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 475-484.	1.8	38
13	Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect. Psychological Medicine, 2010, 40, 1443-1451.	2.7	37
14	Experience of stigma and discrimination reported by people experiencing the first episode of schizophrenia and those with a first episode of depression: The FEDORA project. International Journal of Social Psychiatry, 2015, 61, 438-445.	1.6	37
15	LORETA Functional Imaging in Antipsychotic-Naive and Olanzapine-, Clozapine- and Risperidone-Treated Patients with Schizophrenia. Neuropsychobiology, 2008, 58, 1-10.	0.9	34
16	Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. International Journal of Clinical Practice, 2017, 71, e12997.	0.8	31
17	Mental health services during the first wave of the COVID-19 pandemic in Europe: Results from the EPA Ambassadors Survey and implications for clinical practice. European Psychiatry, 2021, 64, e41.	0.1	30
18	Cognitive Profiles and Functional Connectivity in First-Episode Schizophrenia Spectrum Disorders – Linking Behavioral and Neuronal Data. Frontiers in Psychology, 2019, 10, 689.	1.1	29

Pavel Mohr

#	Article	IF	CITATIONS
19	Value of schizophrenia treatment I: The patient journey. European Psychiatry, 2018, 53, 107-115.	0.1	28
20	Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation. Acta Psychiatrica Scandinavica, 2006, 114, 223-231.	2.2	26
21	Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology, 2018, 235, 491-503.	1.5	26
22	High-Dose Treatment With Haloperidol: The Effect of Dose Reduction. Journal of Clinical Psychopharmacology, 2000, 20, 252-256.	0.7	25
23	Prolactin response to d-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Schizophrenia Research, 1998, 30, 91-99.	1.1	24
24	Compulsory admissions of patients with mental disorders: State of the art on ethical and legislative aspects in 40 European countries. European Psychiatry, 2020, 63, e82.	0.1	23
25	Modulating Inhibitory Control Processes Using Individualized High Definition Theta Transcranial Alternating Current Stimulation (HD Î,tACS) of the Anterior Cingulate and Medial Prefrontal Cortex. Frontiers in Systems Neuroscience, 2021, 15, 611507.	1.2	22
26	ADHD: a hidden comorbidity in adult psychiatric patients. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 83-89.	1.7	19
27	Subject Selection for the Placebo- and Comparator-Controlled Trials of Neuroleptics in Schizophrenia. Journal of Clinical Psychopharmacology, 2000, 20, 240-245.	0.7	18
28	Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuroendocrinology Letters, 2011, 32, 141-7.	0.2	15
29	Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?. Frontiers in Psychiatry, 2021, 12, 781946.	1.3	13
30	Rhythmic finger-tapping task and fast segmentation of neural processing in schizophrenics. Biological Psychiatry, 1996, 40, 1301-1304.	0.7	10
31	Ladislav Haskovec and akathisia: 100th anniversary. British Journal of Psychiatry, 2002, 181, 537-537.	1.7	10
32	Social and functional capacity of schizophrenia patients: A cross-sectional study. International Journal of Social Psychiatry, 2014, 60, 352-358.	1.6	9
33	Value of schizophrenia treatment II: Decision modelling for developing early detection and early intervention services in the Czech Republic. European Psychiatry, 2018, 53, 116-122.	0.1	9
34	Effects of haloperidol treatment on prolactin response to D -fenfluramine challenge in acute schizophrenia. Psychopharmacology, 1999, 141, 322-325.	1.5	8
35	Assessment and Treatment of Negative Symptoms in Schizophrenia—A Regional Perspective. Frontiers in Psychiatry, 2021, 12, 820801.	1.3	8
36	Rhythmic finger tapping task in schizophrenic patients. Schizophrenia Research, 1995, 15, 181.	1.1	7

PAVEL MOHR

#	Article	IF	CITATIONS
37	The role of steroids in the prediction of affective disorders in adult men. Steroids, 2017, 121, 47-53.	0.8	7
38	Teaching Critical Appraisal of Articles on Psychopharmacology. Academic Psychiatry, 2012, 36, 114-7.	0.4	6
39	Circulating C19 steroids and progesterone metabolites in women with acute depression and anxiety disorders. Hormone Molecular Biology and Clinical Investigation, 2016, 26, 153-164.	0.3	6
40	Neuroactive Steroids and Cognitive Functions in First-Episode Psychosis Patients and Their Healthy Siblings. Frontiers in Psychiatry, 2019, 10, 390.	1.3	6
41	FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia. European Psychiatry, 2000, 15, 284s-284s.	0.1	5
42	Prolonged Continuous Theta Burst Stimulation of the Motor Cortex Modulates Cortical Excitability But not Pain Perception. Frontiers in Systems Neuroscience, 2020, 14, 27.	1.2	5
43	Sedative Effects of Low-Dose Risperidone in GAD Patients and Risk of Drug Interactions. Journal of Clinical Psychiatry, 2006, 67, 1307-1308.	1.1	4
44	Prediction of affective disorders in adult men on the basis of steroid profiling. Endocrine Abstracts, 0, , .	0.0	4
45	Altered levels of circulating GABAergic 5α/β-reduced pregnane and androstane steroids in schizophrenic men. Hormone Molecular Biology and Clinical Investigation, 2011, 6, 227-30.	0.3	3
46	Cognitive profiles of healthy siblings of firstâ€episode schizophrenia patients. Microbial Biotechnology, 2021, 15, 554-562.	0.9	3
47	S42.03 Test of Serotonergic Activity in the Brain Predicts Therapeutic Response of Patients with Schizophrenia. European Psychiatry, 2000, 15, 301s-301s.	0.1	1
48	Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update. Dusunen Adam, 2012,	0.0	1
49	Deep brain stimulation in psychiatry. Neuroendocrinology Letters, 2008, 29 Suppl 1, 123-32.	0.2	1
50	Temporal integration reflected in a rhythmic finger tapping task in schizophrenics. International Journal of Psychophysiology, 1997, 25, 64-65.	0.5	0
51	Prolactin response to dexfenfluramine challenge test predicts treatment response and the presence of negative symptoms after haloperidol treatment of acute schizophrenia. Schizophrenia Research, 2000, 41, 241-242.	1.1	0
52	P02.198 Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. European Psychiatry, 2000, 15, 375s-375s.	0.1	0
53	Asymmetry of language activation in families with multiple incidence of schizophrenia. European Psychiatry, 2008, 23, S188.	0.1	0
54	F188. Altered Self-Related Processing in Schizophrenia and its Relation to Psychopathology: An fMRI Study. Biological Psychiatry, 2019, 85, S286.	0.7	0

#	Article	IF	CITATIONS
55	S177. Self-Disturbance Scale and its Application in Schizophrenia. Biological Psychiatry, 2019, 85, S366.	0.7	0
56	Psychopharmacological Agents During Pregnancy and Nursing. , 2021, , 1-27.		0
57	Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuroendocrinology Letters, 2007, 28 Suppl 1, 117-33.	0.2	0